source
- ADC Therapeutics' Zynlonta confirmatory trial shows higher death rates, clouding full approval prospectsADC Therapeutics is pursuing full FDA approval for its antibody-drug conjugate Zynlonta in patients with relapsed or refractory diffuse large B-cell lymphoma. In the confirmatory study presented,…
- ADC biotech Ona Therapeutics raises $86.6M in Series B to move two ADC candidates toward clinicBarcelona-based Ona Therapeutics announced a $86.6 million Series B financing round. The capital will be used to move two antibody‑drug conjugate (ADC) programs into early‑stage clinical testing.…